<SEC-DOCUMENT>0001501697-25-000021.txt : 20250917
<SEC-HEADER>0001501697-25-000021.hdr.sgml : 20250917
<ACCEPTANCE-DATETIME>20250917070330
ACCESSION NUMBER:		0001501697-25-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250915
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250917
DATE AS OF CHANGE:		20250917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		251318774

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xfor-20250915.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e1b55f0a-cc13-4dd8-b5a8-c1b8105c8fd6,g:73c1d40c-1e21-4ebe-8523-9c90d3182944,d:34dbe3ed0e2b494fb26a4704668b72e3-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20250915</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20250915.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-15</xbrli:startDate><xbrli:endDate>2025-09-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i34dbe3ed0e2b494fb26a4704668b72e3_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.068%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"/><td style="width:48.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:100%">FORM  </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr><tr style="height:8pt"><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">September 15, 2025</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.603%"><tr><td style="width:1.0%"/><td style="width:22.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.600%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:22pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.781%"><tr><td style="width:1.0%"/><td style="width:33.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38295</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">27-3181608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.373%"><tr><td style="width:1.0%"/><td style="width:20.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.348%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">61 North Beacon Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">4th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Boston,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02134</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code is </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">857</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report) </span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule  13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.252%"><tr><td style="width:1.0%"/><td style="width:34.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).          </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i34dbe3ed0e2b494fb26a4704668b72e3_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.575%"><tr><td style="width:1.0%"/><td style="width:15.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.05</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Costs Associated with Exit or Disposal Activities.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On September 17, 2025, X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;X4&#8221;) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company&#8217;s long&#8209;term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million. The Company estimates that the workforce reduction will be substantially completed in the third quarter of 2025. The Company estimates that it will incur cash charges of approximately $3.3 million for severance and other employee termination-related costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The estimate of costs that the Company expects to incur related to the workforce reduction as well as the decrease in spending, and the timing thereof are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the actions described above.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.575%"><tr><td style="width:1.0%"/><td style="width:15.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 5.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Departure of Chief Operating Officer, Chief Commercial Officer, Chief Legal &amp; Compliance Officer and Chief Medical Officer</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the workforce reduction discussed above, on September 15, 2025, the Board of Directors (the &#8220;Board&#8221;) determined to terminate the employment of Dr. Mary DiBiase, the Company&#8217;s Chief Operating Officer, Mark Baldry, the Company&#8217;s Chief Commercial Officer, and Natasha Thoren, the Company&#8217;s Chief Legal &amp; Compliance Officer, in each case effective as of September 15, 2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On September 16, 2025, Dr. Christophe Arbet-Engels informed the Company of his resignation as the Company&#8217;s Chief Medical Officer, effective as of September 16, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Appointment of Chief Operating Officer</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On September 16, 2025, the Board appointed John Volpone as Chief Operating Officer of the Company, effective immediately. Mr. Volpone will continue to serve in his role as President of the Company. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Additional information with respect to Mr. Volpone and his appointment as an officer can be found under the heading &#8220;Appointment of President&#8221; in Item 5.02 of the Company&#8217;s Current Report on Form 8-K, filed on August 12, 2025 with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), and is incorporated herein by reference. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.575%"><tr><td style="width:1.0%"/><td style="width:15.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 7.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Regulation FD Disclosure.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On September 17, 2025, the Company issued a press release titled &#8220;X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation,&#8221; a copy of which is attached hereto as Exhibit 99.1.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The information under this Item 7.01, including Exhibit 99.1 hereto, are being furnished herewith and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Forward-Looking Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements regarding the workforce reduction, including estimated costs, timing and expected benefits. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to the workforce reduction, such as the restructuring costs may be greater than anticipated, the restructuring may negatively impact the Company&#8217;s business operations, the restructuring may not generate the intended benefits to the extent or as quickly as anticipated, and other risks and uncertainties described under the caption &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are on file with the SEC, and risks described in other filings that the Company makes with the SEC in the future. Any forward-looking statements contained in this Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex991_2025916release.htm">Press Release, dated September 17, 2025.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.575%"><tr><td style="width:1.0%"/><td style="width:15.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.043%"/><td style="width:0.1%"/></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i34dbe3ed0e2b494fb26a4704668b72e3_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.113%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"> September 17, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David H. Kirske</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">David H. Kirske</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991_2025916release.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie736d0c111864399b18159517a3f5e02_1"></div><div style="min-height:128.88pt;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:top"><div style="margin-bottom:8pt;padding-right:2.77pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:90px;margin-bottom:5pt;vertical-align:text-bottom;width:117px"></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:128%">X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:128%"> </font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:128%">Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M </font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:128%">John Volpone appointed Chief Operating Officer, in addition to his current role as President</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:128%">Dr. Adam Craig, Executive Chairman, to have oversight over clinical development</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:128%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:128%">BOSTON, September 17, 2025 &#8211; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:128%;text-decoration:underline">X4 Pharmaceuticals</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%"> (Nasdaq&#58; XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced a strategic restructuring designed to sharpen operational focus and align resources with the Company&#8217;s long&#8209;term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">As part of this initiative, X4 will reduce its workforce by 50%, a step anticipated to result in annualized cost savings of approximately $13 million. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:128%">Corporate Updates</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:128%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%;padding-left:14.15pt">John Volpone has been appointed Chief Operating Officer (COO), in addition to his current role as President. In this expanded role, Mr. Volpone will oversee day&#8209;to&#8209;day operational management and business execution across the Company.  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:128%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%;padding-left:14.15pt">Dr. Adam Craig, Executive Chairman, will oversee clinical development. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:128%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%;padding-left:14.15pt">As part of the workforce reduction, Natasha Thoren, Chief Legal &#38; Compliance Officer&#59; Mary DiBiase, Chief Operating Officer&#59; and Mark Baldry, Chief Commercial Officer will be exiting the Company.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:128%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%;padding-left:14.15pt">Dr. Christophe Arbet</font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:11pt;font-weight:400;line-height:128%">&#8209;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">Engels, MD, PhD, Chief Medical Officer, is resigning for personal reasons and will remain available to support transition activities. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">&#8220;The new X4 management team has taken the first step in streamlining the organization to effectively execute and complete the 4WARD Phase 3 trial,&#8221; said Dr. Adam Craig, Executive Chairman of X4. &#8220;Over the coming weeks, we plan to continue to drive operational efficiencies, consolidate resources, and strengthen our leadership structure. With these changes, we expect to be well positioned to become a world</font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:11pt;font-weight:400;line-height:128%">&#8209;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">class hematology company, beginning with the advancement of mavorixafor into chronic neutropenia. We remain deeply grateful to our dedicated team for their hard work and commitment during this period of transformation.&#8221;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:128%">About X4 Pharmaceuticals</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI&#174; in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%;text-decoration:underline">4WARD</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">) in people with certain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:128.88pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%;text-decoration:underline">www.x4pharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:128%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:128%">X4 Forward Looking Statements </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; or other similar terms or expressions that concern X4&#8217;s expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding the expected cost savings from the workforce reduction, the expected results of the restructuring of business operations and future plans for the Company. Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4&#8217;s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that&#58; the workforce reduction does not result in the anticipated cost savings described herein&#59; the results of the restructuring of business operations are not as anticipated&#59; and other risks and uncertainties, including those described in the section entitled &#8220;Risk Factors&#8221; in X4&#8217;s most recent Annual Report on X4&#8217;s Form 10-K, as well as in other filings X4 makes with the Securities and Exchange Commission, including its quarterly report on Form 10-Q, from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:128%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:128%">X4 Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">Candice Masse</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%">astr partners</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:128%;text-decoration:underline">candice.masse&#64;astrpartners.com</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xfor-20250915.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e1b55f0a-cc13-4dd8-b5a8-c1b8105c8fd6,g:73c1d40c-1e21-4ebe-8523-9c90d3182944-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20250915" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20250915">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20250915_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20250915_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>xfor-20250915_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e1b55f0a-cc13-4dd8-b5a8-c1b8105c8fd6,g:73c1d40c-1e21-4ebe-8523-9c90d3182944-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_84a9f198-ce4b-4d87-b50e-a9515d8f60b8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bc086e98-d514-43c6-8135-ba225d62173e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d7ce3846-f77b-4a34-a9f4-06dce2f8ee65_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e2696c33-4016-485d-8b9b-5231f2b5e215_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2aaf5b31-7e98-4c28-b56a-b0594bf4da5b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_60018b5d-e501-49b5-894c-8e90884b30db_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_3b0ca810-37b8-4401-8b1a-69ef8bdb46e3_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4ffd4e32-5b67-4aa3-b30c-86f484161d6b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d1076159-1926-4ce9-9410-76960c0bb14d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_79346807-6281-4eda-834f-de80e0e3df64_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d3c94c54-9a3d-4a7d-899b-66b6a9590b2d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0bf0f69f-99c0-4e48-bd66-e8f4816c3ab5_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_fb839e95-cf1f-4cf8-a9e8-912bf27878e1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c193189c-d82c-4857-b50b-dd56cb0c4e1e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d25873d3-1919-4967-8ddb-38d10fd66277_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_48931ac5-f974-43f4-a95a-62fec9c18924_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b9417b62-fc67-489b-8f3d-b527c128e107_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fda6f705-3dc2-4ff2-b5a1-04e5c5f100c6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_09396709-3194-4792-ad0a-ba5c92701ae7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_88448785-f157-433d-9553-a7962a446da9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9f549a21-52fe-48be-8e6f-e7fcb6db05e3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_52dc844b-e75d-48cd-bc7f-f12fc6659186_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ce77cab6-d97f-406d-9c0d-2de03381aff9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_88941649-92a5-409f-ba42-0be4c1a9c454_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>xfor-20250915_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e1b55f0a-cc13-4dd8-b5a8-c1b8105c8fd6,g:73c1d40c-1e21-4ebe-8523-9c90d3182944-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20250915.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f34a98a3-544c-412c-b9ce-bdc46f6149af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_DocumentType_f34a98a3-544c-412c-b9ce-bdc46f6149af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fe624e84-0558-4d78-8b91-f41a3bcfdbbc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_DocumentPeriodEndDate_fe624e84-0558-4d78-8b91-f41a3bcfdbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_64e25bdb-4dce-4311-bc91-37a14b472336" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityRegistrantName_64e25bdb-4dce-4311-bc91-37a14b472336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0d69ffce-31f5-4f77-9c0e-7a4f94f87ab7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0d69ffce-31f5-4f77-9c0e-7a4f94f87ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8e3890e7-0ede-470c-b404-d0b3097b4d7d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityFileNumber_8e3890e7-0ede-470c-b404-d0b3097b4d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6e710193-c327-459d-8358-f8da1108da1c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityTaxIdentificationNumber_6e710193-c327-459d-8358-f8da1108da1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c59cb764-8d81-4016-9f20-3f033d574d27" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityAddressAddressLine1_c59cb764-8d81-4016-9f20-3f033d574d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_0e953de5-ac52-4e45-8f8a-0bb87e9dcc00" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityAddressAddressLine2_0e953de5-ac52-4e45-8f8a-0bb87e9dcc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fe478c6a-4391-41e3-8299-73cf69ff2478" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityAddressCityOrTown_fe478c6a-4391-41e3-8299-73cf69ff2478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a92a6de1-8cc6-4683-accd-613126b528ea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityAddressStateOrProvince_a92a6de1-8cc6-4683-accd-613126b528ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e8e577b9-ab08-4fd1-85c7-ee07e3d42edd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityAddressPostalZipCode_e8e577b9-ab08-4fd1-85c7-ee07e3d42edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_892d51f2-d023-4290-84ea-0e01cbb4afea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_CityAreaCode_892d51f2-d023-4290-84ea-0e01cbb4afea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_49c19a94-f1a7-4f9a-9029-fedd4c573a6b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_LocalPhoneNumber_49c19a94-f1a7-4f9a-9029-fedd4c573a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d549cd00-a686-4055-b000-099b38a49e00" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_WrittenCommunications_d549cd00-a686-4055-b000-099b38a49e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_17f6c670-af5e-4753-816c-2fca9fb63629" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_SolicitingMaterial_17f6c670-af5e-4753-816c-2fca9fb63629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e2b09d93-ea11-41b0-9eea-b121836002f7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_PreCommencementTenderOffer_e2b09d93-ea11-41b0-9eea-b121836002f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_84d75d3f-ac01-4f90-88a4-41d62cee7901" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_84d75d3f-ac01-4f90-88a4-41d62cee7901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2678898c-39d9-4c65-9914-fca26726c714" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_Security12bTitle_2678898c-39d9-4c65-9914-fca26726c714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9a667830-d033-4635-83d3-a9585f349bd1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_TradingSymbol_9a667830-d033-4635-83d3-a9585f349bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_de24055f-0fe3-465e-b246-6e8d68e24768" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_SecurityExchangeName_de24055f-0fe3-465e-b246-6e8d68e24768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dbd436bd-fe75-4bc3-820e-ddef4b8ef94c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityEmergingGrowthCompany_dbd436bd-fe75-4bc3-820e-ddef4b8ef94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_3496e48d-5aed-4703-a7f4-9c11ff5c9f88" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityExTransitionPeriod_3496e48d-5aed-4703-a7f4-9c11ff5c9f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6da35fcb-d22d-4081-aba8-072dfab075b9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_EntityCentralIndexKey_6da35fcb-d22d-4081-aba8-072dfab075b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e0b07c36-91e5-4ed9-b116-681bb6d5f757" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26ea13c6-5098-46fd-9a95-779fcb61a127" xlink:to="loc_dei_AmendmentFlag_e0b07c36-91e5-4ed9-b116-681bb6d5f757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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MRN64*G5)'\1;4+Q?Z_I*&1_P#6N)7ZY<Q[:A.B5Q53FB$"/L&ASBFML>8/>
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M6B@;3KWZM<Q][?ELN6L%*[]S'9$5B PE!=64I%9E]I(+F?/FQ71-FT#[Q!X
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M(W#6W2T=O0J_W.KYS[#!:N:J?]?:+6P[6,7$94RQZ-I;[YPPYK=_R8MYLXU
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MM;<>;PU-W<(6EWH4(O*CO9_>OIO_?<O=#%4JF*@=D\:XCFBNX5!DM1!<:59
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MU01+CS'T='<]S]\%;.>EB)^[$.!'ZV,>8U&$\6UE:"L?L168V#'@W8%F(,N
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MU31M$/+/#A-M7&_VP.EW;>[$0Q"ME:PU)$)"\Q6;*:+U!1!Y/4G3A\U->?8
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!@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 15, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 15,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xfor-20250915.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="xfor-20250915.htm">xfor-20250915.htm</File>
    <File>xfor-20250915.xsd</File>
    <File>xfor-20250915_lab.xml</File>
    <File>xfor-20250915_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "xfor-20250915.htm": {
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20250915",
   "dts": {
    "inline": {
     "local": [
      "xfor-20250915.htm"
     ]
    },
    "schema": {
     "local": [
      "xfor-20250915.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20250915_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20250915_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.x4pharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xfor-20250915.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xfor-20250915.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001501697-25-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001501697-25-000021-xbrl.zip
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M,IY00&2;A2&D<F*LOI2$%2#%9FVN+-ZI"BYBI7+8YXB2%*3HI'O:S)B!B)-
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MX\FNC#Q O@**?V5"Y_E \LJ4EC+;JY)8\^<Z 8TG[<DU^@@EE-7G'N"O%L,
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M@JQ#V.',!]<3=G@0*D<TD4SU @JDH5R\]X8KYU1?QH$$5W/Y8YQ<79"$TB(
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M+$:RPD+ [.D]I.X,&!I\#<4V X!S.7&5)'[!G/@+Y+>_)GCZ?%I%R0$P^^[
M)S!.P_!&G;/ 2U%4C&IG %\FP$!43<Y;HZ-!.8C[?HJ/G^(C)_@H\S5-WXP8
M#5*=@8+P O0"1D%R&_ 4_DD/8E\RW.#3+=FJY01C60T;)C'(C!%(7RTBTFV(
MNQ4_<887 .< $6P (*89AZ+X3U[P9OF1-*=3SI(5*%YU8@0%# M8GV/&YUJ/
MZ,E,^$U3:A/]EK;T& !VN_ X\]D6GR>^-_\P@V[AN8)L_JD^"S__=$3'\X_
MS@X6GH7XZ3Y._84&@:&)A<DB$?Y9 $.,.;>%IW)8A-W=S$.ET(#X/A79 NL\
MD& SI_S3K\2-5_ BR'0?N68P5,H1=<D*QDV9&[D%,UCI\*K0%%?:1-;,9Z&
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M,7][OQ=Z8_AG&(_\SO\ 4$L#!!0    ( &XX,5L&(@J 80(  /D&   1
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M>*0L3^W#+\5%?I?-%0P3 F,&($/$+B@U PS;2ID01D(9"@&Q\A+E$\;$DJR
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MS+;.V1WDK.&H4X8O<[[PZ <+CW2D\/_A,*';,<+#'"#<#$@N[%OG4B>)Y((
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M_P%02P$"% ,4    " !N.#%;\]3!QV\,  #>.0  &               @ $
M    97@Y.3%?,C R-3DQ-G)E;&5A<V4N:'1M4$L! A0#%     @ ;C@Q6_*1
M#[!Q%P  HI0  !$              ( !I0P  'AF;W(M,C R-3 Y,34N:'1M
M4$L! A0#%     @ ;C@Q6P8B"H!A @  ^08  !$              ( !120
M 'AF;W(M,C R-3 Y,34N>'-D4$L! A0#%     @ ;C@Q6Z;$MP^V"@  F5L
M !4              ( !U28  'AF;W(M,C R-3 Y,35?;&%B+GAM;%!+ 0(4
M Q0    ( &XX,5N"!"NF!0<   \U   5              "  ;XQ  !X9F]R
G+3(P,C4P.3$U7W!R92YX;6Q02P4&      4 !0!* 0  ]C@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>xfor-20250915_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xfor-20250915.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2025-09-15</startDate>
            <endDate>2025-09-15</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-09-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38295</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">61 North Beacon Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Boston,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">529-8300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
